longevity researchBiological age blood test: what PhenoAge measures and how to read it

The cheapest, most actionable biological age measurement most men can run is sitting in the chart of their last annual physical. PhenoAge, developed by Morgan Levine and colleagues at Yale and published in Aging in 2018 (Levine et al. 2018), takes nine biomarkers from a standard blood panel and produces a biological age estimate that correlates roughly 0.7 with the much more expensive DNA methylation tests.

The cost is $60 to $120 for the labs, plus a free online calculator. The accuracy is high enough to drive real interventions. And unlike methylation testing, the inputs are individually actionable. You don't just get a number. You get nine biomarkers, each of which points to a different lever.

Below is what each marker in the PhenoAge formula is measuring, how each one shifts with age and lifestyle, and how to read your result.

The nine biomarkers PhenoAge uses#

The PhenoAge algorithm weights nine variables, identified through a NHANES III-based mortality-prediction analysis, plus chronological age. Each variable carries a different coefficient, but the practical ranking of which one drives most variance in healthy men is roughly:

1. Glucose (fasting) — high weight. Elevated fasting glucose, even in the pre-diabetic 95-100 mg/dL range, accelerates PhenoAge by 1 to 3 years versus optimal sub-90 readings.
2. hsCRP (log-transformed) — high weight. Chronic inflammation is one of the strongest mortality signals in middle-aged men. CRP above 2.0 mg/L drives PhenoAge upward sharply.
3. Creatinine — moderate weight. Kidney function marker. Elevations in non-athletic men can flag early renal stress; very lean muscular men may run high benign creatinines.
4. Alkaline phosphatase — moderate weight. Liver and bone turnover marker. Elevations point to liver fat, biliary issues, or bone disease.
5. Albumin — moderate weight (inverse). Low albumin predicts mortality independently in older adults; reflects nutritional status, liver function, and chronic illness.
6. White blood cell count — moderate weight. Elevated WBC at chronic baseline reflects systemic inflammation or smoldering infection.
7. Mean cell volume (MCV) — lower weight. Red cell size; both high and low values flag specific pathologies (B12/folate deficiency, alcohol use, hypothyroidism).
8. Red cell distribution width (RDW) — lower weight. Variability in red cell size; increasingly recognized as an aging marker.
9. Lymphocyte percent — lower weight (inverse). Reflects immune function; lower percent associated with worse outcomes.

The math is freely available in Levine et al. 2018 supplementary materials, and several calculators (Aging.AI, Bioage Labs, the original Yale tool) run the formula in seconds from a typed-in panel.

Why PhenoAge correlates so well with methylation tests#

The intuition behind PhenoAge is that age is not a single biological variable. It is a composite of metabolic, inflammatory, immune, and organ-function processes that all drift in roughly the same direction with time. A single biomarker captures one slice. Nine biomarkers, weighted by their individual mortality association, captures most of the variance.

The Klemera-Doubal method (Klemera & Doubal 2006), which pioneered this multi-biomarker approach, demonstrated that mathematically combining 10 to 12 standard biomarkers reproduces biological age estimates that correlate strongly with methylation-based measurements while costing 90 percent less. Liu and colleagues' 2018 PLoS Medicine paper (Liu et al. 2018) showed PhenoAge predicted morbidity and mortality across diverse subpopulations, including in subgroups where methylation clocks had been less validated.

The blood-based approach has one structural advantage that methylation does not: when PhenoAge is elevated, you can look at the input variables and see which one is pulling the average up. Methylation tests give you a single number with no decomposition. Blood-based tests come with a built-in intervention map.

The actionable trio: glucose, CRP, creatinine#

For most men under 55, three of the nine PhenoAge inputs drive almost all of the modifiable signal.

Fasting glucose. Glucose in the 70-89 mg/dL range is optimal. 90-99 is borderline. 100-125 is pre-diabetic. The PhenoAge weighting penalizes any value above the early 90s, and even a single bad night of sleep can push glucose into the high 90s. The interventions are well-known: low-glycemic carbohydrate timing, fasted morning training, walking 10 to 15 minutes after meals, alcohol reduction, body fat reduction. See fasting glucose optimization for the protocol.

hsCRP. Optimal hsCRP is below 1.0 mg/L. Borderline is 1.0 to 3.0. High-risk is above 3.0. Chronic inflammation drives cardiovascular risk independently of LDL (Ridker et al. 1997), and it is the dominant PhenoAge accelerator in otherwise healthy men with bad sleep or visceral adiposity. The interventions: sleep extension, omega-3 (EPA/DHA at 2-3 g/day), Mediterranean-style eating, alcohol elimination, training volume. See omega-3 EPA DHA dosing.

Creatinine. In athletic men, mildly elevated creatinine often reflects muscle mass and is benign. In sedentary men, elevations flag early renal stress, often driven by chronic NSAID use, hypertension, or pre-diabetic glucose. The interventions: hydration, blood pressure control, NSAID reduction, glucose normalization.

A man whose PhenoAge runs 5 years ahead of chronological is almost always doing so because of one or two of these three markers. Identifying which one is the first step in any meaningful intervention.